For more than 30 years, the 340B Drug Pricing Program has provided financial help to hospitals serving vulnerable communities to manage rising prescription drug costs.

What is the 340B Program? This program, administered by the Health Resources and Services Administration (HRSA), allows 340B hospitals to stretch limited federal resources to reduce the price of outpatient pharmaceuticals for patients and expand health services to the patients and communities they serve. Hospitals use 340B savings to provide, for example, free care for uninsured patients, offer free vaccines, provide services in mental health clinics, and implement medication management and community health programs. According to HRSA, enrolled hospitals and other covered entities can achieve average savings of 25% to 50% in pharmaceutical purchases.

Which organizations are eligible? Several types of hospitals are eligible to participate in the 340B program including critical access hospitals (CAHs), sole community hospitals (SCHs), rural referral centers (RRCs), public and private nonprofit disproportionate share hospitals (DSHs) that serve high numbers of low-income and indigent populations, and free-standing cancer and children’s hospitals. Several types of federal grantee organizations such as community health centers also are eligible to participate in the program.

What are some challenges to the program? Despite rigorous oversight from HRSA and the program’s proven record of expanding access to care for Americans nationwide, critics continue to push to diminish the scope of the program and the benefits it affords eligible providers and their patients.
 

340B Resources

Member Resources

Join the 340B Alliance Banner

The AHA Advocacy Alliance for the 340B program focuses on promoting the value that the 340B program provides to hospitals, patients and communities, as well as preventing attempts to scale back this program. Join the alliance for access to email communications, conference calls and special briefings. Join the Alliance.


Through email communications like alliance emails, action alerts and special messages, the 340B Alliance keeps hospitals informed of the latest news and developments on the program, as well as actions hospital leaders can take to support the program. Learn More

Image of medicine in pharmacy

Latest 340B Content

340B Advocacy Alliance Bulletin
Complete AHA Survey by May 28 on Drug Company 340B Data Policy Compliance
Headline

The AHA today urged Eli Lilly to abandon its 340B Drug Pricing Program claims-data policy and work with the AHA to develop a functional third-party clearinghouse. 
 

340B Advocacy Alliance Bulletin
AHA urges Lilly to drop 340B claims-data policy, proposes neutral clearinghouse.
Action Alert
The House Committee on Ways and Means released draft bill text in advance of its planned May 20 markup.
Letter/Comment
The American Hospital Association expresses concern about Eli Lilly’s January 2026 claims-data policy and invites Lilly to work in good faith with the AHA and our 340B hospital members to find a better path forward than the cycle of escalation that has beset the 340B program in recent years.
340B Advocacy Alliance Bulletin
AHA pushes back on WSJ anti-340B editorial.
Letter/Comment
The AHA asks that as the Senate begins drafting the FY 2027 appropriations bill, it funds health care programs that have proven successful in improving access to quality health care for patients and communities across America.
Letter/Comment
The AHA asks that as the House begins drafting the FY 2027 appropriations bill, it funds health care programs that have proven successful in improving access to quality health care for patients and communities across America.
Headline
The AHA again is asking the Health Resources and Services Administration to take action after Eli Lilly warned hospitals that they could lose access to discounted drug prices unless they comply with new data submission requirements.
Letter/Comment
The American Hospital Association (AHA) writes to alert you to the latest development in connection with the growing number of drug company policies requiring covered entities to submit onerous amounts of claims data in exchange for their statutorily owed 340B discounts.